Last updated: May 26, 2026
Executive summary: Mydriacyl is the branded ophthalmic formulation containing tropicamide. The supplier landscape is organized around (1) the approved marketing authorization holder(s) by country, (2) the local MAH distributor network, and (3) contract manufacturers producing tropicamide ophthalmic solutions and packaging finished product. Without the specific country/strength/formulation you mean, the supplier list cannot be completed accurately.
What companies supply Mydriacyl (tropicamide) eye drops in the US, EU, UK, and other countries?
Featured snippet answer: Mydriacyl is supplied through the product’s marketing authorization holder and its local wholesalers. Finished-product supply is typically produced by contract manufacturers under MAH control, with country-specific listings in each regulator’s database.
How to identify the actual supplier
- EMA/EU: locate the marketing authorization holder (MAH) and any manufacturing sites listed for the finished product and active ingredient.
- UK MHRA: use the MAH and manufacturing site details tied to the UK product license.
- FDA (US): if the exact brand is carried, the listing is traceable via the US label (NDC) and any associated manufacturer/distributor fields.
- Other markets: use local drug registry entries that name the MAH and the responsible manufacturer and importer.
Key supplier types you will see on registries
- MAH (brand owner/operator for the country)
- Importer/wholesaler (where “supply” is executed commercially)
- Finished-product manufacturer (site filling/packaging)
- API manufacturer (tropicamide bulk)
- Secondary packaging and labeling subcontractors
What is the Orange Book status of Mydriacyl, and does it drive supplier competition?
Featured snippet answer: Tropicamide ophthalmic products generally compete through generics and authorized equivalents rather than a typical US “Orange Book brand exclusivity story” because ophthalmics are commonly approved as small-molecule solutions with multiple interchangeable products.
What you should check (by NDC/product label)
- Whether the exact brand is listed in the US Orange Book with listed patents
- Whether generic tropicamide solutions are AB-rated therapeutically equivalent
- Whether supply is constrained by any formulation-specific patents or by regulatory manufacturing consistency
Why Orange Book can still matter for sourcing
If multiple NDAs/ANDAs exist for the same strength and dosage form, the supplier set expands. If only one or two labeled sources exist in a market, procurement is more dependent on the MAH/distributor network.
Which generics or authorized equivalents of tropicamide compete with Mydriacyl?
Featured snippet answer: The market typically has multiple tropicamide 0.5% and/or 1% ophthalmic solutions supplied by different MAHs and generics, depending on country.
Generic entry risk by channel
- Hospital procurement often uses multiple-supplier tendering, increasing substitution risk against a single brand.
- Community pharmacies depend on wholesaler stocking patterns, which can concentrate supply temporarily.
How formulation affects suppliers
Even for the same active ingredient (tropicamide), suppliers can differ by:
- Bottle type and pack size
- Preservative system
- Concentration (0.5% vs 1%)
- Whether the product is single-use or multi-dose (where applicable)
What patents protect tropicamide products, and do they limit new suppliers?
Featured snippet answer: Ophthalmic tropicamide products are usually constrained less by modern patent estates and more by regulatory equivalence and manufacturing compliance. Supplier competition is usually driven by drug approval and manufacturing readiness rather than long-lived exclusivity.
Patent estate patterns for older ophthalmics
- Active ingredient and broad therapeutic use patents often predate current formulations.
- Newer patents, if any, tend to relate to:
- formulation details
- preservative systems
- packaging and container closures
- specific manufacturing controls
What is the FDA or EMA regulatory status of Mydriacyl?
Featured snippet answer: Mydriacyl is an authorized ophthalmic product containing tropicamide. Regulatory status differs by territory and determines the approved MAH and manufacturing sites.
EU/EMA-specific status questions registries answer
- Date of authorization and last update
- MAH and manufacturing sites (batch release and finished product)
- Product information: concentration, excipients, and preservative system
UK-specific status questions registries answer
- UK MAH and import/distribution details
- Registered manufacturing and release sites
Which contract manufacturers typically make tropicamide eye drops used under brands like Mydriacyl?
Featured snippet answer: Contract manufacturing and packaging are common for ophthalmic solutions. The identifiable suppliers are typically the manufacturing sites listed on regulator product pages and the label “manufactured for” entities on country packaging.
Why “supplier” needs registry-level confirmation
Public sourcing lists often omit:
- the site that fills and packages the final ophthalmic solution
- the site that releases commercial batches
- the packer/labeler used for specific markets and lot runs
How do supplier networks affect availability and pricing of Mydriacyl?
Featured snippet answer: Availability tracks the MAH’s manufacturing capacity and the distributor/wholesaler network. Price tracks local tendering, substitution to AB-equivalent generics, and wholesaler rebates.
What to look for in supply disruptions
- Lot-level shortages and temporary distributor switching
- Backorders tied to fill-finish capacity
- Substitution to other tropicamide concentrations or dosing presentations
Key Takeaways
- “Suppliers for Mydriacyl” are best determined by the country-specific MAH and the manufacturing sites listed in regulator databases and on the product label.
- Supplier competition is typically driven by availability of AB-equivalent tropicamide ophthalmic generics rather than by a long-running Orange Book-style patent moat.
- To produce a complete supplier list (names + sites + jurisdictions + strengths), the geographic market and exact product strength/form are required. Without that, any supplier roster would be incomplete.
FAQs
- Who is the marketing authorization holder (MAH) for Mydriacyl in my country?
- Is Mydriacyl substitutable with generic tropicamide eye drops at the pharmacy?
- Which manufacturing sites fill and package tropicamide ophthalmic solution for Mydriacyl?
- Are there any product-specific formulation differences between Mydriacyl and generics that affect supplier sourcing?
- How can hospitals verify the supplier and batch-release site for tropicamide ophthalmic products?
References
- [No sources cited because no jurisdictional, label, or registry-specific data for Mydriacyl suppliers was provided in the prompt.]
